Renalytix Plc
RENX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 31.1% | -32.7% | 14.6% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 40% | 6.8% | 20.6% | 30.9% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -710% | -1,246% | -1,225.8% | -1,774.2% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -680% | -1,461.6% | -1,340.2% | -1,524.4% |
| EPS Diluted | -0.21 | -0.31 | -0.55 | -0.67 |
| % Growth | 32.3% | 43.6% | 17.9% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | £0 | -£0 | £0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |